



**Christoph Renner**

**Kontakt**

Christoph Renner

## Publikationen (23)

Arber C, Baerlocher G, Chalandon Y, Daskalakis M, Duchosal M, Fehr M, Gerull S, Güngör T, Nair G, Pabst T, Passweg J, Piccolruaz B, Renner C, Rüfer A, Schneidawind D, Stuessi G, Zeerleder S, Halter J, Swiss Blood Stem Cell Transplant and Cellular Therapies (SBST) group. Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. *Swiss Med Wkly* 2024; 154:3704.

Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021. *Hematol Oncol* 2023

Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). *EClinicalMedicine* 2023; 64:102221.

Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. *Leukemia* 2023; 37:699–701.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2019; 149:w20031.

Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016. *Swiss Med Wkly* 2018; 148:w14589.

Ture M, Martin-Soelch C, Walt H, Huber G, Fuchs B, Imesch P, Renner C, Perseus J, Zerkiebel N, Schnyder U, Aeschlimann A, Angst F, Barth J, Jenewein J. Use of inpatient rehabilitation for cancer patients in Switzerland: who undergoes cancer rehabilitation?. *Swiss Med Wkly* 2015; 145:w14214.

Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). *J Clin Oncol* 2015; 33:2523–9.

Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2015; 145:w14100.

Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. *Swiss Med Wkly* 2014; 144:w13980.

Hitz F, Bargetzi M, Cogliatti S, Lohri A, Taverna C, Renner C, Mey U. Diagnosis and treatment of mantle cell lymphoma. *Swiss Med Wkly* 2013; 143:w13868.

Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. *Swiss Med Wkly* 2013; 143:w13791.

Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. *Swiss Med Wkly* 2013; 143:w13757.

Motsch N, Renner C, Meister G, Dueck A, Cogliatti S, Tinguely M, Reineke T, Barth S, Zhu J, Imig J, Alles J, Grässer F. MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing. *PloS one* 2012; 7:e42193.

Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). *Leuk Lymphoma* 2012; 54:36-40.

Stenner F, Renner C, Porta C, Buchler T, Knuth A, Stoll S, Siciliano R, Rothermundt C, Cathomas R, Haile S, Liewen H, Chastonay R, Samaras P. A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. *Oncology* 2012; 82:333-340.

Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012; 97:1085-91.

Samaras P, Stenner-Liewen F, Knuth A, Bauer S, Taverna C, Stussi G, Schanz U, Honegger H, Zweifel M, Mischo A, Petrausch U, Siciliano R, Haile S, Blickenstorfer M, Renner C. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. *Swiss Med Wkly* 2011; 141:w13203.

Craig V, Tzankov A, Dirnhofer S, Schlapbach R, Rehrauer H, Neuenschwander S, Renner C, Imig J, Cogliatti S, Müller A. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. *Blood* 2011; 117:6227-36.

Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. *Oncology* 2010; 79:93-97.

Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. *Ann Hematol* 2010; 90:89-94.

Samaras P, Stenner-Liewen F, Knuth A, Zweifel M, Mischo A, Meisel A, Siciliano R, Schaefer N, Petrusch U, Haile S, Heider H, Renner C. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. *Ann Hematol* 2010; 89:783-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)